The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDMTR.L Regulatory News (DMTR)

  • There is currently no data for DMTR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

DeepMatter Appoints Industry Advisors

16 Dec 2019 07:00

RNS Number : 8960W
DeepMatter Group PLC
16 December 2019
 

DeepMatter Group plc

("DeepMatter", the "Company" or "the Group")

 

DeepMatter Appoints Industry Advisors

DeepMatter strengthens its depth of knowledge and industry links in Research & Medicinal Chemistry, Process Chemistry and Automation

 

16 December 2019 - DeepMatter (AIM: DMTR), the AIM-quoted company focusing on digitising chemistry, is delighted to welcome three leading sector figures as industry advisors on its commercial roll-out of DigitalGlassware™. The advisors bring in-depth knowledge in research & medicinal chemistry, process chemistry and industrially focused closed-loop robotics and automation, all target industries for DigitalGlassware, the Company's innovative cloud-based digital chemistry platform that brings recordability, reproducibility and shareability to the lab.

 

The advisors will contribute to the ongoing development of the DigitalGlassware™ strategic roadmap and are as follows:

 

·; Dr Richard Bourne - a leading academic in Process Chemistry. Richard is Associate Professor at the University of Leeds based at the Institute of Process Research and Development, working on rapid process development and continuous flow chemistry. In November 2019, he was announced as a new Royal Academy of Engineering Senior Research Fellow in Digital Manufacturing and Discovery of Pharmaceuticals.

·; Dr John Harris - a pharmaceutical industry consultant with a wealth of research chemistry knowledge and expertise. John was previously Head of the Wellcome Foundation's UK cardiovascular therapeutic area and founder of BioFocus, a highly successful early-stage CRO, now part of the Charles River organisation.

·; Dr David M Parry - an experienced synthetic chemist, with a track record of delivering complex projects within the pharma and biotech sectors. David built and ran a business focused on automated medicinal chemistry, where compounds would be synthesised, then tested in a primary assay on the same platforms, with the results fed back into the software to inform the next round of automated synthesis.

 

Mark Warne, Chief Executive Officer of DeepMatter, commented:

"We believe DigitalGlassware™ has the opportunity to sit at the heart of the digitisation of chemistry, enabling chemists to produce better molecules, faster and ultimately cheaper. We are delighted to welcome Richard, John and David to the DigitalGlassware™ team, each bringing valuable insight from their three areas of specialism. Their expertise will help ensure the platform meets and integrates the needs of these key disciplines, assisting us in the commercial roll-out of our innovative cloud-based digital chemistry platform."

For more information, please contact:

DeepMatter Group plc

T: 0141 548 8156

Mark Warne, Chief Executive Officer

 

 

 

 

Shore Capital (Nominated Adviser and Broker)

 

T: 020 7408 4050

Tom Griffiths

David Coaten

 

 

 

Alma PR

Caroline Forde

Jessica Joynson

Kieran Breheny

 

T: 020 3405 0205

deepmatter@almapr.co.uk

 

About DeepMatter Group plc

 

DeepMatter's long term strategy is to integrate chemistry with technology, thereby enabling a greater use of artificial intelligence and reaching a point where chemicals can be autonomously synthesised through robotics. In the near term this involves the provision of an integrated software, hardware and artificial intelligence enabled platform, DigitalGlassware™, to scientists across research and process development sectors.

 

The DigitalGlassware™ platform allows chemistry experiments to be accurately and systematically recorded, coded and entered into a shared data cloud. The platform is designed to enable chemists to work together effectively; sharing the details of their experiments from anywhere and in real-time, so that work is not needlessly duplicated, time and money wasted, and ultimately so new discoveries may be made faster.

 

Visit: www.deepmatter.io and follow @deepmattergroup

 

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAMMMMZNFZGLZM
Date   Source Headline
13th Apr 20167:00 amRNSPreliminary Results
21st Oct 20157:00 amRNSCompletion of Capital Reorganisation
7th Oct 20151:56 pmRNSResult of Court Hearing
29th Sep 20153:33 pmRNSHolding(s) in Company
28th Sep 201510:02 amRNSHolding(s) in Company
16th Sep 20157:00 amRNSChange of Name
15th Sep 20153:32 pmRNSHolding(s) in Company
15th Sep 201510:02 amRNSDirectors' Interest in Shares
15th Sep 201510:01 amRNSDirectorate Changes
15th Sep 201510:00 amRNSCompletion of Placing and Acquisition
11th Sep 201510:00 amRNSApplication for Admission
10th Sep 201511:16 amRNSResult of General Meeting
25th Aug 20155:10 pmRNSHalf Yearly Report
25th Aug 20155:05 pmRNSAcquisition and related matters
7th Jul 20157:00 amRNSChange of Name
30th Jun 201512:10 pmRNSResult of AGM
4th Jun 20158:35 amRNSReplacement: Final Results
4th Jun 20157:00 amRNSDirectorate Change
4th Jun 20157:00 amRNSFinal Results
8th Jan 20155:56 pmRNSHolding(s) in Company
9th Sep 20147:00 amRNSCompletion of investment in subsidiary
29th Aug 20147:00 amRNSHalf Yearly Report
14th Jul 201411:00 amRNSResult of AGM
30th Jun 20147:00 amRNSFirst commercial sale
17th Jun 20147:00 amRNSFinal Results
17th Mar 20147:00 amRNSGraphene Functionalisation Capabilities
3rd Feb 20147:00 amRNSProject Announcement
24th Jan 20147:00 amRNSOAS launches OntoTM Development Pack for customer
18th Nov 20135:43 pmRNSHolding(s) in Company
30th Oct 20137:00 amRNSDirectorate Change
18th Oct 20137:00 amRNSChange to substantial shareholdings
20th Sep 20137:00 amRNSDirectorate Change
28th Aug 20139:40 amRNSHalf Yearly Report
13th Jun 20135:30 pmRNSAGM Statement
1st May 20137:00 amRNSFinal Results
12th Apr 20131:10 pmRNSHolding(s) in Company
13th Mar 20138:42 amRNSHolding(s) in Company
12th Mar 20138:37 amRNSHolding(s) in Company
6th Mar 20134:03 pmRNSHolding(s) in Company
9th Jan 20137:00 amRNSTechnical Advisory Board Enhanced
7th Jan 20134:25 pmRNSHolding(s) in Company
20th Dec 20121:55 pmRNSHolding(s) in Company
5th Dec 20125:33 pmRNSHolding(s) in Company
12th Nov 20128:51 amRNSHolding(s) in Company
3rd Oct 20127:00 amRNSDirectors' Interest in Shares
26th Sep 20127:00 amRNSInterim Statement
24th Sep 20129:58 amRNSHolding(s) in Company
17th Sep 20129:26 amRNSHolding(s) in Company
1st Aug 20127:00 amRNSAppointment of CEO
15th Jun 201212:00 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.